SAHPRA recalls Arya Pharma Enalapril 10mg
Analysis based on 6 articles · First reported Aug 27, 2026 · Last updated Aug 29, 2026
The recall may temporarily disrupt supply of Enalapril 10mg in South Africa, but the availability of the 5mg alternative mitigates patient impact. Arya Pharma faces reputational and regulatory scrutiny, while Austell Pharmaceuticals may benefit from increased demand for its product.
The South Africa — South African Health Products Regulatory Authority (SAHPRA) ordered a recall of four batches of Enalapril 10mg tablets manufactured by Arya Pharma due to a potency issue identified during post-marketing surveillance. The affected batches, produced in September and October 2024, were found to not meet the required milligram strength, potentially making them less effective. The South Africa — Department of Health (South Africa) reassured patients that the recall does not affect the 5mg version of the drug, which is supplied to public health facilities and has been confirmed to meet quality standards. The 10mg tablets had been approved only as a temporary alternative while the contracted supplier, Austell Pharmaceuticals, resolved a delay in releasing its 5mg product. Patients were urged to continue taking their medication as prescribed.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard